Drugs / J65 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01580696 | Apr 2012 → Jul 2016 | endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneum cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | J65 peptide | “J65 peptide (an attenuated peptide of E39, EIWTFSTKV)” NCT01580696 ↗ |
| Known as | J65 peptide (an attenuated peptide of E39, EIWTFSTKV) | “J65 peptide (an attenuated peptide of E39, EIWTFSTKV)” NCT01580696 ↗ |
| Modality | Peptide | “J65 peptide (an attenuated peptide of E39, EIWTFSTKV)” NCT01580696 ↗ |